PhD defence W.F. (Frederick) Thielen

Although novel treatments for blood cancers can be very expensive (320,000 Euro per patient and more), they are often considered cost-effective when compared to the current standard of care. Even when often neglected future non-medical consumption costs are taken into account in economic evaluation studies, the conclusion about the cost-effectiveness does not change. This is but one conclusion that Frederick Thielen draws in his dissertation “Current Challenges in Health Technology Assessment: Assessing costs and cost-effectiveness of novel treatments in haemato-oncology”. During his PhD trajectory, he studied the cost-effectiveness of two novel and expensive treatments for blood cancers to determine their value for society.

Due to corona, the PhD defences do not take place publicly in the usual way in the Senate Hall of the Professor Andries Querido Room. The candidates will defend their dissertation either in a small group or online.